Cargando…
Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients
This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133801/ https://www.ncbi.nlm.nih.gov/pubmed/27801805 http://dx.doi.org/10.3390/ijms17111800 |
_version_ | 1782471341407993856 |
---|---|
author | Mizushige, Tomoko Kobori, Hiroyuki Hitomi, Hirofumi Nishijima, Yoko Tomoda, Fumihiro Morimoto, Satoshi Kohno, Masakazu Nishiyama, Akira |
author_facet | Mizushige, Tomoko Kobori, Hiroyuki Hitomi, Hirofumi Nishijima, Yoko Tomoda, Fumihiro Morimoto, Satoshi Kohno, Masakazu Nishiyama, Akira |
author_sort | Mizushige, Tomoko |
collection | PubMed |
description | This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (p < 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (<−50%) and non-responders (≥−50%), and a logistic analysis of urinary angiotensinogen before treatment showed the area under the curve as 0.694. When the cutoff value of urinary angiotensinogen before the treatment of 13.9 µg/g Cr was used, the maximum Youden index (0.500, specificity: 11/12 = 91.7% and sensitivity: 7/12 = 58.3%) was obtained. When all patients were re-divided into two groups, those with higher values of urinary angiotensinogen before the treatment (Group H, n = 16) and those with lower values, Group H showed significantly decreased urinary albumin (p < 0.05). Therefore, urinary angiotensinogen could be a prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. |
format | Online Article Text |
id | pubmed-5133801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-51338012016-12-12 Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients Mizushige, Tomoko Kobori, Hiroyuki Hitomi, Hirofumi Nishijima, Yoko Tomoda, Fumihiro Morimoto, Satoshi Kohno, Masakazu Nishiyama, Akira Int J Mol Sci Article This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (p < 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (<−50%) and non-responders (≥−50%), and a logistic analysis of urinary angiotensinogen before treatment showed the area under the curve as 0.694. When the cutoff value of urinary angiotensinogen before the treatment of 13.9 µg/g Cr was used, the maximum Youden index (0.500, specificity: 11/12 = 91.7% and sensitivity: 7/12 = 58.3%) was obtained. When all patients were re-divided into two groups, those with higher values of urinary angiotensinogen before the treatment (Group H, n = 16) and those with lower values, Group H showed significantly decreased urinary albumin (p < 0.05). Therefore, urinary angiotensinogen could be a prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. MDPI 2016-10-27 /pmc/articles/PMC5133801/ /pubmed/27801805 http://dx.doi.org/10.3390/ijms17111800 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mizushige, Tomoko Kobori, Hiroyuki Hitomi, Hirofumi Nishijima, Yoko Tomoda, Fumihiro Morimoto, Satoshi Kohno, Masakazu Nishiyama, Akira Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients |
title | Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients |
title_full | Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients |
title_fullStr | Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients |
title_full_unstemmed | Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients |
title_short | Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients |
title_sort | urinary angiotensinogen could be a prognostic marker of the renoprotection of olmesartan in metabolic syndrome patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133801/ https://www.ncbi.nlm.nih.gov/pubmed/27801805 http://dx.doi.org/10.3390/ijms17111800 |
work_keys_str_mv | AT mizushigetomoko urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients AT koborihiroyuki urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients AT hitomihirofumi urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients AT nishijimayoko urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients AT tomodafumihiro urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients AT morimotosatoshi urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients AT kohnomasakazu urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients AT nishiyamaakira urinaryangiotensinogencouldbeaprognosticmarkeroftherenoprotectionofolmesartaninmetabolicsyndromepatients |